Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Mar 31, 2023
Revenue for the first quarter ended March 31, 2023 was $47.6 million, compared to $3.6 million for the same period in 2022.
As of March 31, 2023, Adaptimmune had cash and cash equivalents of $119.9 million and Total Liquidity1 of $165.6 million, compared to $108.0 million and $204.6 million, respectively, as of December 31, 2022.
1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
For Fiscal Year Ending Dec 31, 2022
For complete information regarding our financials, see our periodic filings